CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
CRISPR Therapeutics AG revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $11.00M | $1.00M | $0 | $35.00M | $35.00M | $35.00M | $35.00M | $200.00M | $200.00M | $270.00M | $370.00M | $170.01M | 82.1% | -68.6% |
| Grant Revenue [Member] | $2.39M | $3.10M | $3.51M | $3.34M | $3.05M | $2.68M | $2.31M | $2.83M | $2.23M | $1.71M | $1.21M | $0 | 17.9% | -21.6% |
By region
From the segment and revenue-disaggregation notes of CRISPR Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.